Thymosin

Summary

Thymosin (CHEMBL412531) is a phase-3 clinical-stage protein; indicated across 8 conditions including decubitus ulcer and st-elevation myocardial infarction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 8 conditions
• Clinical trials: 7
• Chemistry: 3051.3 Da · C128H216N32O51S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL412531
Name	Thymosin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	44286042
Molecular formula	C128H216N32O51S
Molecular weight	3051.3
InChIKey	LCJVIYPJPCBWKS-NXPQJCNCSA-N

SMILES: CC[C@H](C)[C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CO)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CS)N

IUPAC name: (2R)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-2-[[(2R,3S)-2-[[(2R,3S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]pentanedioic acid

Also known as: Thymosin, THYMOSIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
decubitus ulcer	2	MONDO:0004646	EFO:0007067
ST-elevation myocardial infarction	2	MONDO:0041656	EFO:0008585
epidermolysis bullosa	2	MONDO:0006541	EFO:1000690
dry eye syndrome	2	MONDO:0006733	EFO:1000906
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
acute myocardial infarction	2	MONDO:0004781	EFO:0008583
thymus neoplasm	2	MONDO:0005197	EFO:0002626

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00291616	PHASE4	COMPLETED	Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
NCT05658692	PHASE4	UNKNOWN	Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
NCT03663764	PHASE2	UNKNOWN	Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
NCT04268537	PHASE2	UNKNOWN	Immunoregulatory Therapy for 2019-nCoV
NCT05339529	Not specified	RECRUITING	Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
NCT06966687	Not specified	ENROLLING_BY_INVITATION	Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
NCT03509688	Not specified	COMPLETED	The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).